Stock Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – FDA staff say Vertex CF combo works, unclear how

[Reuters] – Vertex Pharmaceuticals Inc’s combination of an experimental compound and an approved drug significantyly improved lung function in cystic fibrosis patients with the most common genetic mutation underlying the disease, FDA staff . . . → Read More: Stock Update: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – FDA staff say Vertex CF combo works, unclear how Similar Articles: Company Update (NASDAQ:VRTX): Vertex Reports First Quarter 2015 Financial Results Stock Update (NASDAQ:VRTX): Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation Stock Update (NASDAQ:VRTX): Vertex to Present at Upcoming Investor Conferences